Lifesci Capital Reiterates “Market Perform” Rating for Repare Therapeutics (NASDAQ:RPTX)

Lifesci Capital restated their market perform rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a research report report published on Friday morning,Benzinga reports.

A number of other research firms have also weighed in on RPTX. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th. Stifel Nicolaus decreased their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Friday.

Repare Therapeutics Trading Down 55.4 %

Shares of NASDAQ RPTX opened at $1.77 on Friday. The stock has a market cap of $75.24 million, a price-to-earnings ratio of -0.89 and a beta of 0.71. Repare Therapeutics has a 12 month low of $1.66 and a 12 month high of $8.49. The company has a 50 day simple moving average of $3.30 and a two-hundred day simple moving average of $3.35.

Institutional Investors Weigh In On Repare Therapeutics

Several hedge funds have recently modified their holdings of RPTX. Acadian Asset Management LLC lifted its position in shares of Repare Therapeutics by 212.1% during the 2nd quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock valued at $1,373,000 after buying an additional 284,036 shares in the last quarter. Blue Owl Capital Holdings LP raised its position in Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after acquiring an additional 250,000 shares during the period. XTX Topco Ltd purchased a new position in Repare Therapeutics during the second quarter valued at $110,000. Marshall Wace LLP acquired a new stake in shares of Repare Therapeutics in the second quarter valued at about $273,000. Finally, Vontobel Holding Ltd. grew its position in shares of Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares during the period. 85.09% of the stock is owned by hedge funds and other institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.